CXCR7 impact on CXCL12 biology and disease

Trends in Molecular Medicine

Volumn 19, Issue 1, 2013, Pages 12-22

  Sánchez Martín, Lorena ^a   Sánchez Mateos, Paloma ^b   Cabañas, Carlos ^a  

^a CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Chemokines; CXCL12; CXCR7; G protein coupled receptors (GPCRs); RDC1; Seven transmembrane spanning receptors (7 TMRs)

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR7; ESTROGEN; STROMAL CELL DERIVED FACTOR 1;

ANGIOGENESIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BONE MARROW; CELL MATURATION; DENDRITIC CELL; EMBRYO DEVELOPMENT; ENDOCYTOSIS; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; LYMPHOCYTE DIFFERENTIATION; METASTASIS; MORPHOGENESIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; POLARIZATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

AUTOIMMUNE DISEASES; CHEMOKINE CXCL11; CHEMOKINE CXCL12; HUMANS; LIGANDS; NEOPLASMS; RECEPTORS, CXCR; SIGNAL TRANSDUCTION;

EID: 84871715854     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2012.10.004     Document Type: Review

References (126)

1. Libert F., et al. Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science 1989, 244:569-572.
2. Heesen M., et al. Cloning and chromosomal mapping of an orphan chemokine receptor: mouse RDC1. Immunogenetics 1998, 47:364-370.
3. Burns J.M., et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 2006, 203:2201-2213.
4. Graham G.J., et al. The biochemistry and biology of the atypical chemokine receptors. Immunol. Lett. 2012, 145:30-38.
5. Libert F., et al. Chromosomal mapping of A1 and A2 adenosine receptors, VIP receptor, and a new subtype of serotonin receptor. Genomics 1991, 11:225-227.
6. Sreedharan S.P., et al. Cloning and expression of the human vasoactive intestinal peptide receptor. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:4986-4990.
7. Kapas S., Clark A.J. Identification of an orphan receptor gene as a type 1 calcitonin gene-related peptide receptor. Biochem. Biophys. Res. Commun. 1995, 217:832-838.
8. Cook J.S., et al. Characterization of the RDC1 gene which encodes the canine homolog of a proposed human VIP receptor. Expression does not correlate with an increase in VIP binding sites. FEBS Lett. 1992, 300:149-152.
9. Nagata S., et al. RDC1 may not be VIP receptor. Trends Pharmacol. Sci. 1992, 13:102-103.
10. McLatchie L.M., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998, 393:333-339.
11. Balabanian K., et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem. 2005, 280:35760-35766.
12. Crump M.P., et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 1997, 16:6996-7007.
13. Veldkamp C.T., et al. The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci. 2005, 14:1071-1081.
14. Drury L.J., et al. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:17655-17660.
15. Ray P., et al. Secreted CXCL12 (SDF-1) forms dimers under physiologic conditions. Biochem. J. 2012, 442:433-442.
16. Veldkamp C.T., et al. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci. Signal. 2008, 1:ra4.
17. Muller A., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
18. Li M., Ransohoff R.M. The roles of chemokine CXCL12 in embryonic and brain tumor angiogenesis. Semin. Cancer Biol. 2009, 19:111-115.
19. Karin N. The multiple faces of CXCL12 (SDF-1α) in the regulation of immunity during health and disease. J. Leukoc. Biol. 2010, 88:463-473.
20. Meiron M., et al. CXCL12 (SDF-1α) suppresses ongoing experimental autoimmune encephalomyelitis by selecting antigen-specific regulatory T cells. J. Exp. Med. 2008, 205:2643-2655.
21. Sanchez-Martin L., et al. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 2011, 117:88-97.
22. Cole K.E., et al. Interferon-inducible T cell α chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 1998, 187:2009-2021.
23. Eva C., Sprengel R. A novel putative G protein-coupled receptor highly expressed in lung and testis. DNA Cell Biol. 1993, 12:393-399.
24. Tripathi V., et al. Differential expression of RDC1/CXCR7 in the human placenta. J. Clin. Immunol. 2009, 29:379-386.
25. + progenitors is functional and is expressed at higher level in human malignant hematopoietic cells. Eur. J. Haematol. 2010, 85:472-483.
26. Liu H., et al. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1α in MSCs. Biochem. Biophys. Res. Commun. 2010, 401:509-515.
27. Van Rechem C., et al. Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1). J. Biol. Chem. 2009, 284:20927-20935.
28. Berahovich R.D., et al. CXCR7 protein is not expressed on human or mouse leukocytes. J. Immunol. 2010, 185:5130-5139.
29. + cells. J. Leukoc. Biol. 2008, 84:1130-1140.
30. Infantino S., et al. Expression and regulation of the orphan receptor RDC1 and its putative ligand in human dendritic and B cells. J. Immunol. 2006, 176:2197-2207.
31. Sierro F., et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:14759-14764.
32. Wang H., et al. The CXCR7 chemokine receptor promotes B cell retention in the splenic marginal zone and serves as a sink for CXCL12. Blood 2012, 119:465-468.
33. Shimizu N., et al. A putative G protein-coupled receptor, RDC1, is a novel coreceptor for human and simian immunodeficiency viruses. J. Virol. 2000, 74:619-626.
34. Humpert M.L., et al. Complementary methods provide evidence for the expression of CXCR7 on human B cells. Proteomics 2012, 12:1938-1948.
35. Berahovich R.D., et al. Nonspecific CXCR7 antibodies. Immunol. Lett. 2010, 133:112-114.
36. Boldajipour B., et al. Control of chemokine-guided cell migration by ligand sequestration. Cell 2008, 132:463-473.
37. Luker K.E., et al. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene 2010, 29:4599-4610.
38. Delgado-Martin C., et al. CXCL12 uses CXCR4 and a signaling core formed by bifunctional Akt, Erk1/2 and mTORC1 to control simultaneously chemotaxis and survival in mature dendritic cells. J. Biol. Chem. 2011, 286:37222-37236.
39. Lavine K.J., Ornitz D. M. Shared circuitry: developmental signaling cascades regulate both embryonic and adult coronary vasculature. Circ. Res. 2009, 104:159-169.
40. Ma Q., et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:9448-9453.
41. Nagasawa T., et al. Defects of B cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382:635-638.
42. Zou Y.R., et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:595-599.
43. Gamba L., et al. Estrogen receptor ESR1 controls cell migration by repressing chemokine receptor CXCR4 in the zebrafish posterior lateral line system. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6358-6363.
44. Boudot A., et al. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells. PLoS ONE 2011, 6:e20898.
45. Werner L., et al. Reciprocal regulation of CXCR4 and CXCR7 in intestinal mucosal homeostasis and inflammatory bowel disease. J. Leukoc. Biol. 2011, 90:583-590.
46. Miao Z., et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:15735-15740.
47. Gebauer F., et al. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J. Surg. Oncol. 2011, 104:140-145.
48. Hattermann K., et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res. 2010, 70:3299-3308.
49. Wang J., et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J. Biol. Chem. 2008, 283:4283-4294.
50. Shimizu S., et al. CXCR7 protein expression in human adult brain and differentiated neurons. PLoS ONE 2011, 6:e20680.
51. Madden S.L., et al. Vascular gene expression in nonneoplastic and malignant brain. Am. J. Pathol. 2004, 165:601-608.
52. Monnier J., et al. CXCR7 is upregulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur. J. Cancer 2012, 48:138-148.
53. D'Alterio C., et al. Concomitant CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer. Curr. Cancer Drug Targets 2010, 10:772-781.
54. Schrevel M., et al. CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients. Br. J. Cancer 2012, 106:1520-1525.
55. Hao M., et al. Role of chemokine receptor CXCR7 in bladder cancer progression. Biochem. Pharmacol. 2012, 84:204-214.
56. Ladoux A., Frelin C. Coordinated upregulation by hypoxia of adrenomedullin and one of its putative receptors (RDC-1) in cells of the rat blood-brain barrier. J. Biol. Chem. 2000, 275:39914-39919.
57. Singh R.K., Lokeshwar B.L. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res. 2011, 71:3268-3277.
58. Zheng K., et al. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res. 2010, 29:31.
59. Petruzziello-Pellegrini T.N., et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J. Clin. Invest. 2012, 122:759-776.
60. Cruz-Orengo L., et al. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J. Exp. Med. 2011, 208:327-339.
61. Schonemeier B., et al. Enhanced expression of the CXCl12/SDF-1 chemokine receptor CXCR7 after cerebral ischemia in the rat brain. J. Neuroimmunol. 2008, 198:39-45.
62. Watanabe K., et al. Pathogenic role of CXCR7 in rheumatoid arthritis. Arthritis Rheum. 2010, 62:3211-3220.
63. Roland J., et al. Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. Blood 2003, 101:399-406.
64. Gosling J., et al. Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:5061-5066.
65. Berchiche Y.A., et al. Direct assessment of CXCR4 mutant conformations reveals complex link between receptor structure and Gαi activation. J. Biol. Chem. 2007, 282:5111-5115.
66. Thelen M., Thelen S. CXCR7, CXCR4 and CXCL12: an eccentric trio?. J. Neuroimmunol. 2008, 198:9-13.
67. Naumann U., et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS ONE 2010, 5:e9175.
68. Ulvmar M.H., et al. Atypical chemokine receptors. Exp. Cell Res. 2011, 317:556-568.
69. Thelen M., et al. Chemokine receptor oligomerization: functional considerations. Curr. Opin. Pharmacol. 2010, 10:38-43.
70. Lagane B., et al. CXCR4 dimerization and β-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood 2008, 112:34-44.
71. Salanga C.L., et al. Modulation of chemokine receptor activity through dimerization and crosstalk. Cell. Mol. Life Sci. 2009, 66:1370-1386.
72. Levoye A., et al. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113:6085-6093.
73. Luker K.E., et al. Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J. 2009, 23:823-834.
74. Deupi X., Standfuss J. Structural insights into agonist-induced activation of G-protein-coupled receptors. Curr. Opin. Struct. Biol. 2011, 21:541-551.
75. Xu F., et al. Structure of an agonist-bound human A2A adenosine receptor. Science 2011, 332:322-327.
76. Rasmussen S.G., et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 2011, 477:548-557.
77. Percherancier Y., et al. Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J. Biol. Chem. 2005, 280:9895-9903.
78. Luker K.E., et al. Imaging ligand-dependent activation of CXCR7. Neoplasia 2009, 11:1022-1035.
79. Proost P., et al. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 2007, 110:37-44.
80. Graham G.J. D6 and the atypical chemokine receptor family: novel regulators of immune and inflammatory processes. Eur. J. Immunol. 2009, 39:342-351.
81. Decaillot F.M., et al. CXCR7/CXCR4 heterodimer constitutively recruits β-arrestin to enhance cell migration. J. Biol. Chem. 2011, 286:32188-32197.
82. Grymula K., et al. Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int. J. Cancer 2010, 127:2554-2568.
83. Odemis V., et al. CXCR7 is an active component of SDF-1 signalling in astrocytes and Schwann cells. J. Cell Sci. 2010, 123:1081-1088.
84. Rajagopal S., et al. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:628-632.
85. Wang Y., et al. CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron 2011, 69:61-76.
86. Dambly-Chaudiere C., et al. Control of cell migration in the development of the posterior lateral line: antagonistic interactions between the chemokine receptors CXCR4 and CXCR7/RDC1. BMC Dev. Biol. 2007, 7:23.
87. Zabel B.A., et al. The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells. Mol. Cancer 2011, 10:73.
88. Valentin G., et al. The chemokine SDF1a coordinates tissue migration through the spatially restricted activation of Cxcr7 and Cxcr4b. Curr. Biol. 2007, 17:1026-1031.
89. Whalen E.J., et al. Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol. Med. 2011, 17:126-139.
90. Shenoy S.K., Lefkowitz R.J. β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol. Sci. 2011, 32:521-533.
91. Sánchez-Alcañiz J.A., et al. Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron 2011, 69:77-90.
92. Palmesino E., et al. Differences in CXCR4-mediated signaling in B cells. Immunobiology 2006, 211:377-389.
93. Luttrell L.M., Gesty-Palmer D. Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol. Rev. 2010, 62:305-330.
94. Duda D.G., et al. CXCL12 (SDF1α)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?. Clin. Cancer Res. 2011, 17:2074-2080.
95. Sun X., et al. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010, 29:709-722.
96. Zabel B.A., et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J. Immunol. 2009, 183:3204-3211.
97. Kalatskaya I., et al. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol. Pharmacol. 2009, 75:1240-1247.
98. Yoshida D., et al. Signalling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1α, in AtT20 mouse adrenocorticotrophic hormone-secreting pituitary adenoma cells. J. Neuroendocrinol. 2009, 21:481-488.
99. Sasado T., et al. Distinct contributions of CXCR4b and CXCR7/RDC1 receptor systems in regulation of PGC migration revealed by medaka mutants kazura and yanagi. Dev. Biol. 2008, 320:328-339.
100. Mazzinghi B., et al. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J. Exp. Med. 2008, 205:479-490.
101. Cubedo N., et al. CXCR4 and CXCR7 cooperate during tangential migration of facial motoneurons. Mol. Cell. Neurosci. 2009, 40:474-484.
102. Friedl P., Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2009, 10:445-457.
103. Aman A., Piotrowski T. Wnt/β-catenin and Fgf signaling control collective cell migration by restricting chemokine receptor expression. Dev. Cell 2008, 15:749-761.
104. Haas P., Gilmour D. Chemokine signaling mediates self-organizing tissue migration in the zebrafish lateral line. Dev. Cell 2006, 10:673-680.
105. Mendez-Ferrer S., et al. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008, 452:442-447.
106. + macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J. Exp. Med. 2011, 208:261-271.
107. Ehninger A., Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J. Exp. Med. 2011, 208:421-428.
108. Ara T., et al. Long-term hematopoietic stem cells require stromal cell-derived factor-1 for colonizing bone marrow during ontogeny. Immunity 2003, 19:257-267.
109. Sugiyama T., et al. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25:977-988.
110. Lapidot T., Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp. Hematol. 2002, 30:973-981.
111. Broxmeyer H.E., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J. Exp. Med. 2005, 201:1307-1318.
112. Noda M., et al. CXCL12-CXCR4 chemokine signaling is essential for NK cell development in adult mice. Blood 2011, 117:451-458.
113. Shiozawa Y., et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest. 2011, 121:1298-1312.
114. To L.B., et al. How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011, 118:4530-4540.
115. Hernandez L., et al. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res. 2011, 13:R128.
116. Garcia M., et al. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:11538-11542.
117. Wurth R., et al. Expression of CXCR7 chemokine receptor in human meningioma cells and in intratumoral microvasculature. J. Neuroimmunol. 2011, 234:115-123.
118. Lucchesi W., et al. Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. J. Virol. 2008, 82:7456-7466.
119. Bakondi B., et al. SDF-1α secreted by human CD133-derived multipotent stromal cells promotes neural progenitor cell survival through CXCR7. Stem Cells Dev. 2011, 20:1021-1029.
120. Tavor S., et al. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation. Leukemia 2008, 22:2151-2158.
121. Patel J.R., et al. CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11062-11067.
122. Melchionna R., et al. Induction of myogenic differentiation by SDF-1 via CXCR4 and CXCR7 receptors. Muscle Nerve 2010, 41:828-835.
123. Janas M.L., Turner M. Stromal cell-derived factor 1α and CXCR4: newly defined requirements for efficient thymic β-selection. Trends Immunol. 2010, 31:370-376.
124. Collins A., et al. RUNX proteins in transcription factor networks that regulate T cell lineage choice. Nat. Rev. Immunol. 2009, 9:106-115.
125. Hernandez-Lopez C., et al. Stromal cell-derived factor 1/CXCR4 signaling is critical for early human T cell development. Blood 2002, 99:546-554.
126. Jones S.W., et al. Theorphan G-protein coupled receptor RDC1: evidence for a role in chondrocyte hypertrophy and articular cartilage matrix turnover. Osteoarthritis Cartilage 2006, 14:597-608.